A Phase 2 interventional study of FST-100 and FST-100 (Component #1) in Acute Adenoviral Conjunctivitis, sponsored by Shire. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.
Sponsored by Shire · Phase 2, Interventional, and Treatment
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.
361 studies on the registry are indexed under Conjunctivitis; 17 are open to participants now.
This study's enrollment of 176 is above the median of 100 across 299 interventional studies indexed under Conjunctivitis.
Browse Conjunctivitis studies →Shire is the lead sponsor of 346 studies on the registry; 2 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 47 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: FST-100
Drug: FST-100 (Component #1)
Drug: FST-100 Vehicle
0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
0.6% PVP-Iodine ophthalmic solution alone
FST-100 Vehicle
Adenoviral eradication and clinical resolution of the infection
Time frame: 6-7 days
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Conjunctivitis, Inclusion
Shire